CANCER IMMUNOLOGY IMMUNOTHERAPY
CANCER IMMUNOLOGY IMMUNOTHERAPY(英文缩写 CANCER IMMUNOL IMMUN),ISSN 0340-7004,eISSN 1432-0851 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-21 至 2026-09-21，按本站收录文献的发表日期统计。
指标来源：jcr_cas_ifqb
期刊简介
暂无简介。
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 6.630 | Q1 |
| 2022 | 5.800 | Q1 |
| 2023 | 4.600 | Q1 |
| 2024 | 5.100 | Q1 |
| 2025 | 5.800 | Q1 |
CANCER IMMUNOLOGY IMMUNOTHERAPY 最新收录文献
-
1. Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer-a monocentric experience.
PMID:作者:日期:2026-09-04Combination immunotherapy has shown encouraging activity across multiple solid tumors. We report the complete and consecutive cohort of patients with locally advanced oral squamous cell carcinoma (OSCC) treated at a single center within the prospective, multicenter, randomized phase 2 BelieveIT-201 …
-
5. The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.
PMID:作者:日期:2026-08-04Natural killer (NK) cells are critical components of the innate immune system, renowned for their ability to recognize and eliminate malignant and infected cells without prior sensitization. NK cell immunotherapy encompasses various approaches, including adoptive transfer of ex vivo expanded NK cell…
-
6. Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immunotherapy efficacy in ARID1A-deficient pancreatic cancer.
PMID:作者:日期:2026-07-21Pancreatic ductal adenocarcinoma (PDAC) is largely resistant to immune checkpoint blockade (ICB) due to its highly immunosuppressive tumor microenvironment. How to switch the "immune-cold" microenvironment to "immune hot" one is a clinical unmet need. We recently generated a genetically engineered P…
-
7. Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.
PMID:作者:日期:2026-07-20Multiple myeloma (MM), a hematological malignancy, remains an incurable disease due to the development of resistance to the treatment; thus, there is an urgent need for new and effective therapeutic strategies, particularly for patients who do not respond to standard therapies. High levels of Cluste…
-
8. Mast cells in tumors: dual roles and therapeutic potential.
PMID:作者:日期:2026-07-19Mast cells (MCs) are tissue-resident immune cells that accumulate in the tumor microenvironment (TME) and display marked functional plasticity. Rather than acting through fixed pro-tumor or anti-tumor phenotypes, tumor-associated MCs acquire functional programs shaped by tumor type, spatial localiza…
-
9. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma.
PMID:作者:日期:2026-07-18MUC1 is frequently overexpressed in esophageal squamous cell carcinoma (ESCC), but MUC1-targeted CAR-NK cells remain unexplored in this malignancy. MUC1 expression was assessed by IHC in 90 ESCC specimens, 47 paired adjacent normal tissues, and normal human organs. MUC1-targeted CAR-NK cells were ge…
-
10. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression.
PMID:作者:日期:2026-07-17Thyroid cancer is the most common endocrine malignancy. Although surgery remains the primary treatment, advanced disease frequently recurs or metastasizes, and subsequent therapies yield suboptimal outcomes. Immunotherapy holds promise, yet the underlying immune-evasion mechanisms remain incompletel…